GLMD
Galmed Pharmaceuticals Ltd (GLMD)
Healthcare • NASDAQ • $0.61-1.47%
- Symbol
- GLMD
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.61
- Daily Change
- -1.47%
- Market Cap
- $4.03M
- Trailing P/E
- N/A
- Forward P/E
- -0.59
- 52W High
- $2.34
- 52W Low
- $0.41
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 0.62
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, …
Company websiteResearch GLMD on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.